DERMATA THERAPEUTICS, INC. Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture
DERMATA THERAPEUTICS, INC. (DRMA) reported Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture of $1.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement
us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation · last filed 2026-08-11
- DERMATA THERAPEUTICS, INC. shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2026-06-30 was $0.00.
- DERMATA THERAPEUTICS, INC. shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2026-03-31 was $1.50M.
- DERMATA THERAPEUTICS, INC. shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2022-03-31 was $531.57K, a 54.18% decline year-over-year.
- DERMATA THERAPEUTICS, INC. shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2021-09-30 was $142.66K.
- DERMATA THERAPEUTICS, INC. shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2025 was $1.50M.
- DERMATA THERAPEUTICS, INC. shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2021 was $1.59M.
| Period end | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 3 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 6 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 9 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.50M 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | $1.50M 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $1.50M 10-K · filed 2026-03-26 | |||
| 2022-03-31 | $531.57K 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $1.59M 10-K · filed 2022-03-28 | |||
| 2021-09-30 | $142.66K 10-Q · filed 2021-11-15 | $256.64K derived: sum of 2 quarters · filed 2021-11-15 | $1.42M derived: sum of 3 quarters · filed 2022-05-16 | |
| 2021-06-30 | $113.99K 10-Q · filed 2021-11-15 | $1.27M derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2021-03-31 | $1.16M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |